NCT06567041View on ClinicalTrials.gov

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

December 10, 2025

Study Completion Date

December 10, 2025

Conditions
Diabetes Mellitus, Type 2Obesity
Interventions
DRUG

NNC0519-0130

NNC0519-0130 will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Trial Locations (1)

14050

Parexel International GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06567041 - A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes | Biotech Hunter | Biotech Hunter